Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers

Summary

Pneumonia is frequently associated with changes in coagulation and fibrinolysis in the bronchoalveolar space. To determine the effect of lipopolysaccharide (LPS) on the hemostatic balance in the human lung, six healthy subjects inhaled nebulized LPS or saline in a randomized cross-over study and bronchoalveolar lavage fluid was obtained six hours thereafter. LPS induced soluble tissue factor and thrombin-antithrombin complexes and inhibited plasminogen activator activity in BALF. Additionally plasminogen activator inhibitor type 1 production was upregulated after LPS inhalation. LPS also elicited local activation of neutrophils (release of elastase, myeloperoxidase and bactericidal/permeability increasing protein) and secretion of interleukin (IL)-6 and IL-8. Inhalation of LPS by healthy humans reproduces major features of the procoagulant response to inflammatory and infectious lung diseases and may be used as a novel model to evaluate pathogenetic mechanisms and new interventions.

Keywords

Lipopolysaccharide - lung - coagulation - fibrinolysis - human

• References

• 1 Levi M, Schultz MJ, Rijneveld AW. et al. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31: S238-42.
• 2 Gunther A, Mosavi P, Heinemann S. et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-62.
• 3 Schultz MJ, Millo J, Levi M. et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-5.
• 4 Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31: S213-20.
• 5 de Jonge E, Dekkers PE, Creasey AA. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9.
• 6 Hollenstein UM, Pernerstorfer T, Homoncik M. et al. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis 2002; 186: 1270-6.
• 7 Jagielo PJ, Thorne PS, Watt JL. et al. Grain dust and endotoxin inhalation challenges produce similar inflammatory responses in normal subjects. Chest 1996; 110: 263-70.
• 8 Wesselius LJ, Nelson ME, Bailey K. et al. Rapid lung cytokine accumulation and neutrophil recruitment after lipopolysaccharide inhalation by cigarette smokers and nonsmokers. J Lab Clin Med 1997; 129: 106-14.
• 9 Michel O, Nagy AM, Schroeven M. et al. Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med 1997; 156: 1157-64.
• 10 van der Veen MJ, van der Zee JS. Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir. Eur Respir J 1999; 13: 668-72.
• 11 Bresser P, Out TA, van Alphen L. et al. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 947-52.
• 12 Branger J, van den Blink B, Weijer S. et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 4070-7.
• 13 Verheijen JH, Mullaart E, Chang GT. et al. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-9.
• 14 Thorn J. The inflammatory response in humans after inhalation of bacterial endotoxin: a review. Inflamm Res 2001; 50: 254-61.
• 15 O'Grady NP, Preas HL, Pugin J. et al. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med 2001; 163: 1591-8.
• 16 Nocker RE, Weller FR, Out TA. et al. A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma. Am J Respir Crit Care Med 1999; 159: 1499-505.
• 17 Li N, Soop A, Sollevi A. et al. Multi-cellular activation in vivo by endotoxin in humans--limited protection by adenosine infusion. Thromb Haemost 2000; 84: 381-7.
• 18 Miller DL, Welty-Wolf K, Carraway MS. et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26: 650-8.
• 19 Rijneveld AW, Weijer S, Florquin S. et al. Thrombomodulin mutant mice with a strongly reduced capacity to generate Activated Protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103: 1702-9.
• 20 Enkhbaatar P, Okajima K, Murakami K. et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide- induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 2000; 162: 1752-9.
• 21 van der Poll T, Levi M, Hack CE. et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-9.
• 22 Levi M, van der Poll T, ten CH. et al. Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med 1998; 158: 92-8.
• 23 Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35: 545-54.